Lithium clearance measurements during recombinant interleukin 2 treatment: Tubular dysfunction in man

Steven D. Heys*, Oleg Eremin, Christopher R. Franks, John Broom, Paul H. Whiting

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N-acetyl-βD-glucosaminidase were also measured in the patients' urine, before treatment, during treatment, and then 2 days and 23 days after rIL2 therapy had finished. Significant reductions in clearances of creatinine, sodium, and lithium were observed. The fractional excretions of sodium and lithium were also reduced. Twenty-three days following cessation of rIL2 treatment, there was still a significant reduction in creatinine clearance compared with pretreatment values (p < 01). The clearances of sodium and lithium were also reduced compared with pretreatment values although this did not achieve significance. The fractional reabsorption of sodium and water by the proximal nephron increased during rIL2 treatment, from 0.707 ± 0.030 (pretreatment) to 0.793 ± 0.043. This increased reabsorption of sodium and water persisted, rising to 0.849 ± 0.029, 2 days following cessation of treatment (p < 001, means ± SEM). Twenty-three days later this had returned toward the pretreatment value, being 0.781 ± 0.036. The fractional reabsorption of sodium by the distal nephron was also significantly elevated, both during and 2 days after completing rIL2 treatment. Twenty-three days after cessation of rIL2, this value had returned to the pretreatment value. However, in contrast, the fractional reabsorp-tion of water by the distal nephron demonstrated no change during rIL2 treatment, but 2 days posttreatment was significantly reduced and remained low for a further 3 weeks.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalRenal Failure
Volume15
Issue number2
DOIs
Publication statusPublished - 1993

Fingerprint

Lithium
Interleukin-2
Sodium
Nephrons
Therapeutics
Water
Creatinine
Hexosaminidases
Withholding Treatment
Colorectal Neoplasms
Urine
Kidney
Enzymes

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Nephrology

Cite this

Lithium clearance measurements during recombinant interleukin 2 treatment : Tubular dysfunction in man. / Heys, Steven D.; Eremin, Oleg; Franks, Christopher R.; Broom, John; Whiting, Paul H.

In: Renal Failure, Vol. 15, No. 2, 1993, p. 195-201.

Research output: Contribution to journalArticle

Heys, Steven D. ; Eremin, Oleg ; Franks, Christopher R. ; Broom, John ; Whiting, Paul H. / Lithium clearance measurements during recombinant interleukin 2 treatment : Tubular dysfunction in man. In: Renal Failure. 1993 ; Vol. 15, No. 2. pp. 195-201.
@article{cc6cfd55612e4d51af4b7b79676526eb,
title = "Lithium clearance measurements during recombinant interleukin 2 treatment: Tubular dysfunction in man",
abstract = "Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N-acetyl-βD-glucosaminidase were also measured in the patients' urine, before treatment, during treatment, and then 2 days and 23 days after rIL2 therapy had finished. Significant reductions in clearances of creatinine, sodium, and lithium were observed. The fractional excretions of sodium and lithium were also reduced. Twenty-three days following cessation of rIL2 treatment, there was still a significant reduction in creatinine clearance compared with pretreatment values (p < 01). The clearances of sodium and lithium were also reduced compared with pretreatment values although this did not achieve significance. The fractional reabsorption of sodium and water by the proximal nephron increased during rIL2 treatment, from 0.707 ± 0.030 (pretreatment) to 0.793 ± 0.043. This increased reabsorption of sodium and water persisted, rising to 0.849 ± 0.029, 2 days following cessation of treatment (p < 001, means ± SEM). Twenty-three days later this had returned toward the pretreatment value, being 0.781 ± 0.036. The fractional reabsorption of sodium by the distal nephron was also significantly elevated, both during and 2 days after completing rIL2 treatment. Twenty-three days after cessation of rIL2, this value had returned to the pretreatment value. However, in contrast, the fractional reabsorp-tion of water by the distal nephron demonstrated no change during rIL2 treatment, but 2 days posttreatment was significantly reduced and remained low for a further 3 weeks.",
author = "Heys, {Steven D.} and Oleg Eremin and Franks, {Christopher R.} and John Broom and Whiting, {Paul H.}",
year = "1993",
doi = "10.3109/08860229309046152",
language = "English",
volume = "15",
pages = "195--201",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Lithium clearance measurements during recombinant interleukin 2 treatment

T2 - Tubular dysfunction in man

AU - Heys, Steven D.

AU - Eremin, Oleg

AU - Franks, Christopher R.

AU - Broom, John

AU - Whiting, Paul H.

PY - 1993

Y1 - 1993

N2 - Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N-acetyl-βD-glucosaminidase were also measured in the patients' urine, before treatment, during treatment, and then 2 days and 23 days after rIL2 therapy had finished. Significant reductions in clearances of creatinine, sodium, and lithium were observed. The fractional excretions of sodium and lithium were also reduced. Twenty-three days following cessation of rIL2 treatment, there was still a significant reduction in creatinine clearance compared with pretreatment values (p < 01). The clearances of sodium and lithium were also reduced compared with pretreatment values although this did not achieve significance. The fractional reabsorption of sodium and water by the proximal nephron increased during rIL2 treatment, from 0.707 ± 0.030 (pretreatment) to 0.793 ± 0.043. This increased reabsorption of sodium and water persisted, rising to 0.849 ± 0.029, 2 days following cessation of treatment (p < 001, means ± SEM). Twenty-three days later this had returned toward the pretreatment value, being 0.781 ± 0.036. The fractional reabsorption of sodium by the distal nephron was also significantly elevated, both during and 2 days after completing rIL2 treatment. Twenty-three days after cessation of rIL2, this value had returned to the pretreatment value. However, in contrast, the fractional reabsorp-tion of water by the distal nephron demonstrated no change during rIL2 treatment, but 2 days posttreatment was significantly reduced and remained low for a further 3 weeks.

AB - Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N-acetyl-βD-glucosaminidase were also measured in the patients' urine, before treatment, during treatment, and then 2 days and 23 days after rIL2 therapy had finished. Significant reductions in clearances of creatinine, sodium, and lithium were observed. The fractional excretions of sodium and lithium were also reduced. Twenty-three days following cessation of rIL2 treatment, there was still a significant reduction in creatinine clearance compared with pretreatment values (p < 01). The clearances of sodium and lithium were also reduced compared with pretreatment values although this did not achieve significance. The fractional reabsorption of sodium and water by the proximal nephron increased during rIL2 treatment, from 0.707 ± 0.030 (pretreatment) to 0.793 ± 0.043. This increased reabsorption of sodium and water persisted, rising to 0.849 ± 0.029, 2 days following cessation of treatment (p < 001, means ± SEM). Twenty-three days later this had returned toward the pretreatment value, being 0.781 ± 0.036. The fractional reabsorption of sodium by the distal nephron was also significantly elevated, both during and 2 days after completing rIL2 treatment. Twenty-three days after cessation of rIL2, this value had returned to the pretreatment value. However, in contrast, the fractional reabsorp-tion of water by the distal nephron demonstrated no change during rIL2 treatment, but 2 days posttreatment was significantly reduced and remained low for a further 3 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0027468729&partnerID=8YFLogxK

U2 - 10.3109/08860229309046152

DO - 10.3109/08860229309046152

M3 - Article

C2 - 8469787

AN - SCOPUS:0027468729

VL - 15

SP - 195

EP - 201

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 2

ER -